- Home
- GRAF vs AQST Comparison
GRAF vs AQST Comparison
Compare GRAF & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRAF
- AQST
- Stock Information
- Founded
- GRAF 2021
- AQST 2004
- Country
- GRAF United States
- AQST United States
- Employees
- GRAF N/A
- AQST N/A
- Industry
- GRAF
- AQST Biotechnology: Pharmaceutical Preparations
- Sector
- GRAF
- AQST Health Care
- Exchange
- GRAF NYSE
- AQST Nasdaq
- Market Cap
- GRAF 294.4M
- AQST 272.9M
- IPO Year
- GRAF 2024
- AQST 2018
- Fundamental
- Price
- GRAF $10.45
- AQST $3.83
- Analyst Decision
- GRAF
- AQST Strong Buy
- Analyst Count
- GRAF 0
- AQST 6
- Target Price
- GRAF N/A
- AQST $10.67
- AVG Volume (30 Days)
- GRAF 6.6K
- AQST 1.4M
- Earning Date
- GRAF 01-01-0001
- AQST 08-05-2025
- Dividend Yield
- GRAF N/A
- AQST N/A
- EPS Growth
- GRAF N/A
- AQST N/A
- EPS
- GRAF 0.32
- AQST N/A
- Revenue
- GRAF N/A
- AQST $54,228,000.00
- Revenue This Year
- GRAF N/A
- AQST N/A
- Revenue Next Year
- GRAF N/A
- AQST $45.71
- P/E Ratio
- GRAF $32.41
- AQST N/A
- Revenue Growth
- GRAF N/A
- AQST 5.29
- 52 Week Low
- GRAF $9.03
- AQST $2.12
- 52 Week High
- GRAF $11.02
- AQST $5.80
- Technical
- Relative Strength Index (RSI)
- GRAF N/A
- AQST 69.48
- Support Level
- GRAF N/A
- AQST $3.62
- Resistance Level
- GRAF N/A
- AQST $3.80
- Average True Range (ATR)
- GRAF 0.00
- AQST 0.19
- MACD
- GRAF 0.00
- AQST 0.03
- Stochastic Oscillator
- GRAF 0.00
- AQST 99.25
About GRAF GRAF GLOBAL CORP
Graf Global Corp is a blank check company.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.